Inoue D - Search Results

1

Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma.

Hashimoto T, Abe M, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T. Hashimoto T, et al. Among authors: inoue d. Br J Haematol. 2004 Apr;125(1):38-41. doi: 10.1111/j.1365-2141.2004.04864.x. Br J Haematol. 2004. PMID: 15015966 Free article.

2

Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma.

Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D, Matsumoto T. Abe M, et al. Among authors: inoue d. Blood. 2002 Sep 15;100(6):2195-202. Blood. 2002. PMID: 12200385 Free article.

3

[Clinical application of metabolic bone markers in hematologic malignancies].

Hashimoto T, Abe M, Inoue D. Hashimoto T, et al. Among authors: inoue d. Clin Calcium. 2001 Jul;11(7):873-8. Clin Calcium. 2001. PMID: 15775592 Japanese.

4

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion.

Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T. Abe M, et al. Among authors: inoue d. Blood. 2004 Oct 15;104(8):2484-91. doi: 10.1182/blood-2003-11-3839. Epub 2004 Jun 8. Blood. 2004. PMID: 15187021 Free article.

5

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, Tanaka Y, Shibata H, Hashimoto T, Ozaki S, Kido S, Inoue D, Matsumoto T. Oshima T, et al. Among authors: inoue d. Blood. 2005 Nov 1;106(9):3160-5. doi: 10.1182/blood-2004-12-4940. Epub 2005 Jul 19. Blood. 2005. PMID: 16030194 Free article.

6

Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-kappaB ligand and vascular endothelial growth factor to enhance osteoclastogenesis.

Shibata H, Abe M, Hiura K, Wilde J, Moriyama K, Sano T, Kitazoe K, Hashimoto T, Ozaki S, Wakatsuki S, Kido S, Inoue D, Matsumoto T. Shibata H, et al. Among authors: inoue d. Clin Cancer Res. 2005 Sep 1;11(17):6109-15. doi: 10.1158/1078-0432.CCR-05-0181. Clin Cancer Res. 2005. PMID: 16144909

7

Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.

Tanaka Y, Abe M, Hiasa M, Oda A, Amou H, Nakano A, Takeuchi K, Kitazoe K, Kido S, Inoue D, Moriyama K, Hashimoto T, Ozaki S, Matsumoto T. Tanaka Y, et al. Among authors: inoue d. Clin Cancer Res. 2007 Feb 1;13(3):816-23. doi: 10.1158/1078-0432.CCR-06-2258. Clin Cancer Res. 2007. PMID: 17289872

8

[Recent advances in basic research of bone metabolism].

Inoue D, Matsumoto T. Inoue D, et al. Nihon Rinsho. 2002 Mar;60 Suppl 3:25-33. Nihon Rinsho. 2002. PMID: 11979916 Review. Japanese. No abstract available.

9

[Selective estrogen receptor modulator (SERM)].

Inoue D, Matsumoto T. Inoue D, et al. Nihon Rinsho. 2005 Mar;63 Suppl 3:613-8. Nihon Rinsho. 2005. PMID: 15813137 Review. Japanese. No abstract available.

10

[Medical treatment of osteoporosis].

Inoue D, Matsumoto T. Inoue D, et al. Nihon Rinsho. 2006 Sep;64(9):1633-8. Nihon Rinsho. 2006. PMID: 16972671 Review. Japanese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

938 results

Search Page

Filters